Travere Therapeutics

Investor Fact Sheet

At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow.

Ticker	TVTX
Market Cap (B)[1]	$4.8
Shares Outst (M)[2]	94.6
Cash (M)[3]	$472

[1] As of 10/31/26. [2] As of 09/30/26. [3] Cash, cash equivalents and marketable securities as of September 30, 2026.

Four Strategic Growth Pillars Support Durable Long-Term Value Creation

CORE GROWTH DRIVER

Continued growth of FILSPARI in IgAN

Established leadership with continued demand in evolving treatment landscape

FILSPARI (sparsentan)

CORE GROWTH DRIVER

Successful launch of FILSPARI in FSGS

First approved medicine with rapid early adoption supported by high unmet need and prescriber familiarity

FILSPARI (sparsentan)

POTENTIAL NEXT APPROVED MEDICINE

Pegtibatinase as potential first disease modifying therapy for classical HCU

Topline data from pivotal Phase 3 HARMONY Study expected in 2H27

Pegtibatinase

NEW GROWTH PLATFORM

Civorebrutinib complements the rare kidney disease portfolio

Pipeline-in-a-product potential with multi-billion-dollar global opportunity

CIVOREBRUTINIB

FILSPARI: Significant Growth Opportunity with Strong Commercial Synergies Across IgAN and FSGS

>100,000

addressable patients with IgAN and FSGS in the U.S.[1]

>$3B

estimated potential sales opportunity for FILSPARI in the U.S. by 2033

~7,000


target prescribers treating most patients with IgAN and FSGS

>80%


overlap between IgAN and FSGS prescribers[2]

[1] Source: Estimated based on independent market research and data on file.
[2] Source: Travere market research.

FILSPARI Commercial Momentum Accelerates as FSGS Expands the Growth Opportunity



Pipeline of Potential First-in-Class Programs Targeting Rare Kidney and Metabolic Diseases



Abbreviations: IgAN: IgA nephropathy; FSGS: focal segmental glomerulosclerosis; HCU: classical homocystinuria, MCD: minimal change disease; pMN: primary membranous nephropathy.
[1] In September 2024, the FDA granted full approval of FILSPARI (sparsentan) to slow kidney function decline in adults with primary IgAN who are at risk for disease progression. [2] In April 2026, the FDA granted approval of FILSPARI (sparsentan) to reduce proteinuria in adult and pediatric patients aged 8 years and older with FSGS without nephrotic syndrome. CSL Vifor has exclusive commercial rights for sparsentan in Europe, Australia, New Zealand, Bahrain, Brazil, Chile, Israel, Kuwait, Oman, Qatar, Saudi Arabia and the United Arab Emirates. Chugai Pharmaceutical has exclusive commercial rights for sparsentan in Japan, South Korea, and Taiwan. [3] Topline efficacy data anticipated in 2H 2027. [4] Current Everest Medicines study. [5] As part of the ongoing basket study conducted by Everest Medicines.

Business Strategy

- Strengthen FILSPARI's leadership across IgAN and FSGS through sustained commercial execution.
- Execute Phase 3 HARMONY Study to position pegtibatinase as the first potential disease-modifying therapy for HCU.
- Progress development planning for civorebrutinib across multiple immune-mediated kidney diseases.
- Strong balance sheet to execute on key strategic priorities.
- Continued investment in strategic rare nephrology and metabolic disease opportunities.

Travere Therapeutics, Inc. | 3611 Valley Centre Drive, Suite 300, San Diego, CA 92130 | ir.travere.com | email: ir@travere.com

This investor fact sheet contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations and involve risks and uncertainties. Forward-looking statements may include statements regarding clinical development programs and trials (including our Phase 3 HARMONY Study), regulatory filings and regulatory decisions and the timing thereof, estimates regarding the commercial opportunity for FILSPARI and the estimated sizes of patient populations, and other forward-looking information. No forward-looking statement can be guaranteed and actual results may differ materially from those stated or implied by forward-looking statements. We undertake no obligation to publicly update any forward-looking statement, except as required under applicable law. Forward-looking statements should be evaluated together with the many risks and uncertainties that affect our business, particularly those mentioned under the "Risk Factors" heading of our Forms 10-K and 10-Q that are filed with the SEC.